BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34380513)

  • 21. Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer.
    Hu JM; Chou YC; Wu CC; Hsiao CW; Lee CC; Chen CT; Hu SI; Liu WT; Jao SW
    J Chin Med Assoc; 2016 Sep; 79(9):477-88. PubMed ID: 27329402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa.
    Tan SX; Pumpalova Y; Rogers AM; Bhatt K; Herbst CL; Ruff P; Neugut AI; Hur C
    Cancer Med; 2023 Jul; 12(14):15515-15529. PubMed ID: 37318753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival.
    Aoyama T; Oba K; Honda M; Muto M; Mayanagi S; Maeda H; Kanda M; Kashiwabara K; Sakamoto J; Yoshikawa T
    Int J Clin Oncol; 2023 Jun; 28(6):777-784. PubMed ID: 37039949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.
    Pu H; Yang W; Liu M; Pang X; Chen Y; Xiong Q
    Sci Rep; 2024 Mar; 14(1):6889. PubMed ID: 38519578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
    van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
    Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H; Cassidy J
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
    Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
    Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
    Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
    Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods.
    Zhang C; Zhan Y; Ni K; Liu Z; Xin R; Han Q; Li G; Ping H; Liu Y; Zhao X; Wang W; Yan S; Sun J; Zhang Q; Wang G; Zhang Z; Zhang X; Hu X
    BMC Cancer; 2022 Nov; 22(1):1156. PubMed ID: 36352365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer.
    Woo IT; Park JS; Kang BW; Park SY; Kim HJ; Choi GS; Gwang Kim J
    Dis Colon Rectum; 2020 Oct; 63(10):1455-1465. PubMed ID: 32969889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
    Yoshimatsu K; Ishibashi K; Koda K; Yokomizo H; Oda N; Oshiro M; Kato H; Oya M; Nakajima H; Ooki S; Maekawa H; Matsunami T; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Yokoyama M; Ishida H
    Surg Today; 2019 Jun; 49(6):498-506. PubMed ID: 30953164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
    Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
    Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.